Farmas USA

No se, el del jefe, imagino....
No tengo ni idea de si tengo un permiso especial...
Yo puedo operar en pre desde las 10 de la mañana hora nuestra, hasta las 2 de la madrugada en after hora nuestra....
Ahora mismo, si quisiera vender ARRY a 5,80, ningún problema....

Por cierto, bien el pre de ARRY, de momento....

http://www.streetinsider.com/Management+Changes/Array+Biopharma+%28ARRY%29+Names+New+CFO/10872625.html?si_client=intbro

DMPI, a ver si seguimos con la estela del viernes....
Hoy, conferencia, mañana conferencia y creo que a finales de semana, liberacion de datos de Fase I/II para VAL-083 en GBM...

The Company's abstract entitled, "Post-Market Clinical Trial of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non-Small Cell Lung Cancer," will be presented on Tuesday, September 8, 2015 from 9:30 a.m. - 4:30 p.m. PDT during a poster session focused on Treatment of Advanced Diseases - NSCLC.

VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 25, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on the development and commercialization of new cancer therapies, today announced that it will be presenting at the 17th Annual Rodman & Renshaw Global Investment Conference being held September 9-10, 2015, at the St. Regis Hotel in New York, New York.
Jeffrey Bacha, DelMar's president and CEO, will present on Wednesday, September 9, 2015 at 3:50 p.m. Eastern Time. As part of his presentation, Mr. Bacha will present a corporate overview, including recent progress of DelMar's Phase II clinical trial of VAL-083 (dianhydrogalactitol) for the treatment of refractory glioblastoma multiforme (GBM) and future plans to initiate clinical trials with VAL-083 as a potential treatment for non-small cell lung cancer (NSCLC) and other solid tumors in collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co., Ltd.

VANCOUVER, British Columbia and MENLO PARK, Calif., July 9, 2015 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (DMPI) ("DelMar" and the "Company"), a biopharmaceutical company focused on developing and commercializing proven cancer therapies in new orphan drug indications, today announced that the Company will be presenting updated clinical data on its lead product candidate, VAL-083, from its Phase I/II clinical trial in patients with refractory glioblastoma multiforme (GBM), the most common and deadly form of human brain cancer.
DelMar's abstract entitled, "Update on Phase 1/2 study of VAL-083 (dianhydrogalactitol) in patients with recurrent malignant glioma," will be presented during a poster session at GBM2015, II International Symposium on Clinical and Basic Investigation in Glioblastoma, being held September 9 - 12, 2015, in Toledo, Spain.

SGNL orden de compra a 1,60 (por si no deja hueco)

OCAT

Cuidao que ya tenemos al primer conejillo de indias preparado! :))

First Patient Enrolled in Ocata Therapeutics’ Phase 2 Study for Dry AMD

http://ir.ocata.com/press-releases/detail/2796/first-patient-enrolled-in-ocata-therapeutics-phase-2

(Results from First Cohort Expected in the Second Quarter of 2016)

CTIX, a ver si superamos esos 2,05$ hoy....

it will be concluding its Phase 1 trial of the novel compound Kevetrin in patients with advanced solid tumors at the completion of the current cohort. The final cohort requires that six patients be treated at the maximum tolerated dose. Three of the six patients in the cohort have already completed the required treatments with Kevetrin. Cellceutix has been advised that the remaining three patients are currently being recruited. - See more at: http://cellceutix.com/cellceutix-plans-for-phase-2-clinical-trial-in-ovarian-cancer/#sthash.mChWPGJP.dpuf O sea, que la liberacion de datos de Fase I está cercana.....

THLD en zona importante, normalmente suele rajarse a estos niveles pero me da que eata vez va a ser diferente ... ya veremos ...

THLD

cachis, me olvide en darle un pellizco a las REGN en 500 como dije ... argggg

Consideras que si llega a los 4.60 aprox puede confirmar la rotura de la lateralidad en la que estaba (3.90-4.50) ?

THLD